Infliximab for Injection

INFITIV for Injection is a monoclonal antibody that targets and inhibits tumor necrosis factor-alpha (TNF-), a cytokine involved in systemic inflammation. It is used to treat a variety of autoimmune and inflammatory diseases. The primary uses of Infliximab for Injection include:

1. Rheumatoid Arthritis:

   - Used in combination with methotrexate to reduce the signs and symptoms of rheumatoid arthritis, slow the progression of joint damage, and improve physical function in adult patients who have had an inadequate response to methotrexate alone.

2. Crohn's Disease:

   - Approved for the treatment of moderate to severe Crohn's disease in adults and children who have not responded adequately to conventional therapies. It is also used to maintain clinical remission and prevent flare-ups.

3. Ulcerative Colitis:

   - Used to treat moderate to severe ulcerative colitis in patients who have not responded to other treatments. It helps reduce the signs and symptoms, induce and maintain remission, and promote healing of the intestinal lining.

4. Ankylosing Spondylitis:

   - Indicated for the treatment of active ankylosing spondylitis, a form of arthritis that primarily affects the spine. Infliximab helps reduce pain, stiffness, and inflammation associated with this condition.

5. Psoriatic Arthritis:

   - Used to treat active psoriatic arthritis, helping to reduce joint pain, swelling, and improve physical function. It can also help with the skin symptoms associated with psoriasis.

6. Plaque Psoriasis:

   - Indicated for the treatment of chronic, severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and who have not responded to other systemic treatments.

7. Pediatric Crohn's Disease:

   - Approved for use in children aged 6 years and older with moderate to severe Crohn's disease who have not responded adequately to conventional therapies.

INFITIV is typically administered as an intravenous infusion under the supervision of a healthcare professional. The dosing schedule involves an initial series of infusions followed by maintenance doses. Because Infliximab can suppress the immune system, patients are closely monitored for infections, including tuberculosis, and other potential side effects like infusion reactions, liver damage, and heart failure.